NICHE INVESTMENT WITH A BROAD REACH
We are a highly specialized biotech investor. We currently manage the largest and most diversified portfolio of ALS related companies worldwide. We are also globally among the most diversified VC funds in neurodegeneration in general with the ambition to build out this position. The knowledge we gather through our portfolio, and our longstanding relationships with a global ALS-related network of scientists, clinicians, foundations, and patient advocates, differentiates us from other investors.
- Our focus provides us with unparalleled access to information and opportunities, and a competitive advantage when it comes to sourcing potential investments, performing due diligence on the science, and supporting our portfolio companies after investing.
- Our focus also shortens our timelines when it comes to an investment decision, as we have often already followed the companies being considered for investment for some time, which proves to be crucial when closing a round of finance together with other investors.
Eventually the effect of our investments reaches far. All of our portfolio companies target ALS and other diseases such as Alzheimers, Parkinsons and all focusing on innovative approaches that target cures or at least a modification of the course of the diseases. Therefore, any drug that will come out our portfolio potentially is groundbreaking and a leap forward for patients.
The effect of our investments may reach far. All of our portfolio companies target ALS in particular and other neurodegenerative diseases in general, diseases such as Alzheimer’s and Parkinson’s. Our investments do have in common that they do focus on innovative approaches that target cures or at least a modification of the course of the diseases. Therefore, any drug and / or method that will come out our portfolio potentially is groundbreaking and a leap forward for patients.